Circassia brings biotech craze from US to London
Circassia launched the first large biotechnology IPO in London on Thursday after a run of listings from the sector in the US. The UK company, which hopes to find a cure for cat allergies, is set to raise £175m through the deal.
The US has seen strong activity in the biotechnology sector, with a number of listings including some from European firms. But although Circassia has opted for a UK listing, US investors are still expected to make up much of the demand.
However, market sentiment has been more patchy recently,
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: email@example.com or find out more online here.